Guangjing Bio: Leveraging Proprietary Technologies to Penetrate China's High-End POCT Market
Guangjing Biological Technology Co., Ltd. was established in February 2010 and is primarily engaged in the research, development, production, and sales of in vitro diagnostic (POCT) products and infection control solutions. Leveraging functional nanomaterials as its technological foundation, Guangjing Biological’s products are applicable to various fields, including cardiovascular disease, women’s health, infection control, cancer screening, drug abuse testing, and food safety.The company’s multiple products, such as the Heart-type Fatty Acid-Binding Protein (H-FABP) Detection Kit and the Neutrophil Gelatinase-Associated Lipocalin (NGAL) Detection Kit,Filling the gap in related technical fields both domestically and internationally.
China’s POCT Sector Sees Rapid Development as Guangjing Biological Technology Seizes Industry Opportunities
POCT technology is characterized by its speed, simplicity, and ease of sampling. It enables rapid diagnostic results, significantly reduces testing time, and improves the efficiency of diagnosis and treatment, thereby facilitating the rational utilization of hospital resources. He Aimin, Founder and CEO of Guangjing Biological Technology (Suzhou) Co., Ltd., stated that the original intention behind establishing the company was to develop high-value-added, high-tech, and excellent domestically produced POCT products.
Global POCT Market Structure Chart (Source: GF Securities)
In terms of the global market size structure for point-of-care testing (POCT), the United States currently accounts for approximately 50%, Europe for over 30%, while Japan, China, and India hold relatively small shares. However, given its large population, the Asia-Pacific region is a key focus for the future development of the POCT market. In 2009, China’s POCT market accounted for less than 3% of the global total, significantly lower than its share in the global pharmaceutical market. Nevertheless, with the advancement of healthcare reforms driving increased financial investment in primary healthcare, growing demand for various emergency diagnostic services, and the continuous introduction of POCT concepts and technologies, China’s POCT industry holds tremendous potential. It was against this industry backdrop that Guangjing Biological Technology (Suzhou) Co., Ltd. was established.
POCT Market CAGR (Source: GF Securities)
The early development of point-of-care testing (POCT) began in the mid-20th century, primarily relying on dry chemistry test strips for blood glucose and urinary glucose detection. Subsequently, immunoassay technologies such as immunochromatography and dot immunogold filtration drove advancements in POCT for infectious diseases and cardiac markers. The emergence of biosensors based on microfluidics marked a significant turning point for POCT, accelerating its miniaturization and intelligent development. Currently, POCT is progressively achieving high-throughput, multi-target detection, and, building on increasingly mature communication technologies, is evolving toward integration with remote data centers. Future POCT products will not only enable convenient and rapid testing and analysis but also integrate remote data terminals and medical resources to optimize treatment, thereby contributing to the construction of a comprehensive health ecosystem.
R&D is not limited to proprietary intellectual property products in the medical field; the company leverages its technological advantages to capture the domestic market.
With the development of POCT technology, several large companies have focused on this field. Guangjing Bio’s competitive advantage lies in its independently developed products and proprietary patented technologies. “The company pursues an innovation-driven path rather than a market-driven one; new technology is the key,” said He Aimin. Currently, the company’s products have obtained CFDA and CE certifications. Among them, the product developed in collaboration with Kimberly-Clark is the only POCT product in China protected by world-class intellectual property rights. Guangjing Bio mainly engages inR&D and Sales of Diagnostic Instruments.
The company’s main products include POCT medical instruments, test kits, and biofilm reactors. Notably, Guangjing has developed a next-generation time-resolved fluorescence immunochromatography platform, achieving a leap from first-generation colloidal gold technology to third-generation time-resolved fluorescence technology. This advancement significantly enhances the detection sensitivity and linear range of point-of-care diagnostics, while enabling precise quantification. The platform offers advantages such as ease of operation, rapid results, low cost, stable reagents, convenient storage and portability, and traceable test results. It can be widely applied across multiple fields, including medical health, customs quarantine, agriculture and animal husbandry, forestry, fire safety, environmental monitoring, and food testing.
Currently, the reagent kits and instruments developed by the company can be applied to the rapid diagnosis of critical illnesses, with an instrument detection time of approximately 20–30 seconds per sample. Applications include rapid diagnosis of acute myocardial infarction, diagnosis of heart failure, diagnosis of pulmonary embolism, and detection of bacterial infection markers. The company will also actively expand its testing services in the field of chronic diseases. Unlike Micro-Nano Core, Guangjing Biological Technology’s products belong to the immunodiagnostics category.
Guangjing Biological Technology’s devices now support one-click upload of results to the cloud, enabling cloud-based data storage with on-demand download, upload, and shared analysis. The team is also working diligently to develop a practical user-facing mobile app to enhance post-test diagnostic and therapeutic services.
Overseas-Educated PhD Team Develops First-Generation Handheld Device
When discussing the most memorable experience during the entrepreneurial journey, Dr. He Aimin stated that building a strong team and seeking like-minded individuals to join was both the most challenging and the most unforgettable aspect. Guangjing Biological Technology boasts robust team resources. Its founder and CEO, Dr. He Aimin, is an overseas high-tech talent who conducted biotechnology research in the United States prior to establishing the company. All members of the R&D team hold doctoral degrees, the management team comprises professionals with work and management experience at Fortune 500 companies, and the sales team has cultivated deep expertise in the industry over many years. This powerful team has enabled Guangjing Biological Technology to achieve steady growth. Currently, the company has established collaborations with numerous renowned research institutions, universities, and multinational corporations both domestically and internationally, includingBangs Laboratories, BioSurface Technologies, and others. He Aimin stated that the company has currently developed its first-generation handheld in vitro diagnostic instrument, which integrates internet technology to enable thisThe product can cover various levels from county-level hospitals to tertiary hospitals.This approach facilitates the implementation of a tiered diagnosis and treatment system, enabling more institutions to adopt point-of-care testing (POCT) technology and making rational use of township-level medical resources.
Next, Guangjing Biological Technology will strengthen channel development and integration, while continuing to advance personalized treatment technologies.